Sanofi Pasteur announced that it has begun shipping the 2010–2011 formulation of Fluzone (trivalent inactivated “split virus” influenza vaccine [Types A and B]). This season’s vaccine will include the 2009 H1N1 pandemic strain among the three vaccine strains. Sanofi Pasteur expects to supply more than 70 million doses of Fluzone this flu season.
Fluzone is intended for use in children ≥6 months of age through adulthood and is available as a no-preservative vaccine in single-dose prefilled syringes or vials for both children and adults. Fluzone vaccine is also provided in multi-dose vials, which contain preservative. Fluzone High-Dose is available for adults ≥65 years of age in single-dose, no-preservative, prefilled syringes. Fluzone High-Dose vaccine contains 60mcg of hemagglutinin per strain of influenza virus in the vaccine as compared to 15mcg of influenza virus hemagglutinin per strain of influenza virus in standard-dose adult Fluzone vaccine.
For more information call (800) VACCINE or visit www.fluzone.com.